WMT

102.33

+0.1%↑

PG

159.59

+0.32%↑

KO

67.95

+0.79%↑

PM

164.75

+1.4%↑

PEP

143.14

+1.04%↑

WMT

102.33

+0.1%↑

PG

159.59

+0.32%↑

KO

67.95

+0.79%↑

PM

164.75

+1.4%↑

PEP

143.14

+1.04%↑

WMT

102.33

+0.1%↑

PG

159.59

+0.32%↑

KO

67.95

+0.79%↑

PM

164.75

+1.4%↑

PEP

143.14

+1.04%↑

WMT

102.33

+0.1%↑

PG

159.59

+0.32%↑

KO

67.95

+0.79%↑

PM

164.75

+1.4%↑

PEP

143.14

+1.04%↑

WMT

102.33

+0.1%↑

PG

159.59

+0.32%↑

KO

67.95

+0.79%↑

PM

164.75

+1.4%↑

PEP

143.14

+1.04%↑

Search

Hims & Hers Health Inc

Open

BrancheKonsumgüter defensiv

48.01 -3.34

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

47.5

Max

49.91

Schlüsselkennzahlen

By Trading Economics

Einkommen

-7M

43M

Verkäufe

-41M

545M

KGV

Branchendurchschnitt

53.608

31.444

Gewinnspanne

7.801

Angestellte

1,637

EBITDA

-29M

37M

Empfehlungen

By TipRanks

Empfehlungen

Neutral

12-Monats-Prognose

+1.22% upside

Dividenden

By Dow Jones

Nächstes Ergebnis

3. Nov. 2025

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

-4.6B

9.6B

Vorheriger Eröffnungskurs

51.35

Vorheriger Schlusskurs

48.01

Nachrichtenstimmung

By Acuity

50%

50%

69 / 150 Ranking in Consumer defensive

Technischer Score

By Trading Central

Vertrauen

Bullish Evidence

Hims & Hers Health Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

5. Aug. 2025, 00:05 UTC

Heiße Aktien

Stocks to Watch: Palantir Technologies, Hims & Hers Health, Vertex Pharmaceuticals, Kyndryl

29. Apr. 2025, 12:54 UTC

Wichtige Markttreiber

Hims & Hers Rallies After Novo Nordisk Deal on Wegovy

4. Apr. 2025, 22:38 UTC

Heiße Aktien

Stocks to Watch: Eli Lilly, Novo Nordisk, Hims & Hers, Maxeon Solar Technologies

1. Apr. 2025, 23:15 UTC

Wichtige Markttreiber

Hims & Hers Adds Eli Lilly's Zepbound in Expansion of Weight-Loss Offerings -- 2nd Update

25. Feb. 2025, 15:33 UTC

Wichtige Markttreiber

Novo Nordisk Shares Rise as Hims & Hers to Stop Mimicking Weight-Loss Drugs

18. Nov. 2024, 19:07 UTC

Wichtige Markttreiber

Hims & Hers Stock Climbs After Former Regulator Autor Joins Board

14. Okt. 2024, 15:02 UTC

Wichtige Markttreiber

Hims & Hers Health Shares Jump After FDA Set to Reconsider Limits on Knockoff Weight-Loss Drugs

5. Aug. 2025, 20:44 UTC

Ergebnisse

These Stocks Moved the Most Today: Palantir, Vertex, Hims & Hers, Coinbase, BP, and More -- Barrons.com

5. Aug. 2025, 18:17 UTC

Ergebnisse

These Stocks Are Moving the Most Today: Palantir, Vertex, Hims & Hers, Coinbase, BP, and More -- Barrons.com

5. Aug. 2025, 17:26 UTC

Ergebnisse
Akquisitionen, Fusionen, Übernahmen

Hims & Hers Had a Tough Quarter. Weight-Loss Drugs Are Only One Problem. -- Barrons.com

5. Aug. 2025, 15:25 UTC

Ergebnisse

Correction to These Stocks Are Moving the Most Today: Palantir, Vertex, Hims & Hers, Caterpillar, BP, and More -- Barrons.com

5. Aug. 2025, 11:27 UTC

Ergebnisse

Update: These Stocks Are Moving the Most Today: Palantir, Vertex, Hims & Hers, AMD, BP, and More -- Barrons.com

5. Aug. 2025, 10:55 UTC

Ergebnisse

Update: These Stocks Are Moving the Most Today: Palantir, Vertex, Hims & Hers, AMD, BP, and More -- Barrons.com

5. Aug. 2025, 10:36 UTC

Ergebnisse

Update: These Stocks Are Moving the Most Today: Palantir, Vertex, Hims & Hers, AMD, BP, and More -- Barrons.com

29. Juli 2025, 16:55 UTC

Ergebnisse

The Obesity Bubble Has Finally Burst. Novo Nordisk Shares Drop 21%. -- Barrons.com

24. Juni 2025, 10:26 UTC

Market Talk

Novo Nordisk Sends Clear Message on Copycat Drugs -- Market Talk

3. Juni 2025, 15:03 UTC

Akquisitionen, Fusionen, Übernahmen

Hims & Hers Seeks Growth in Europe as Weight-Loss Business Shifts -- Barrons.com

7. Mai 2025, 13:56 UTC

Ergebnisse

Novo Nordisk Stock Jumps After Earnings. Compounding Market's Growth Took it By Surprise -- Barrons.com

6. Mai 2025, 14:24 UTC

Ergebnisse

Hims & Hers Stock Is Higher After Earnings. The Sales Outlook Looks Low. -- Barrons.com

30. Apr. 2025, 09:30 UTC

Top News

Why New Wegovy Deals Won't Restore Novo's Obesity Lead -- Heard on the Street -- WSJ

2. Apr. 2025, 16:53 UTC

Top News

Hims & Hers Zepbound Offering Won't Bring Needed Sales Boom -- Analysis

19. März 2025, 15:54 UTC

Top News

Sale of Ozempic Knockoffs Are Supposed to End Soon. Telehealth Companies Aren't Happy. -- WSJ

21. Feb. 2025, 23:20 UTC

Ergebnisse

These Stocks Moved the Most Today: UnitedHealth, Alibaba, Rivian, Celsius, Booking, Block, Akamai, Hims & Hers, and More -- Barrons.com

10. Feb. 2025, 12:00 UTC

Top News

Hims Super Bowl Ad Spotlights Weight-Loss Drug Copycats as Clock Ticks on Their Business -- Heard on the Street -- WSJ

19. Dez. 2024, 17:16 UTC

Top News

FDA Says Shortage of Eli Lilly's Zepbound is Over, But Gives Compounders a Grace Period -- Barrons.com

19. Dez. 2024, 15:14 UTC

Top News

Eli Lilly's Zepbound Shortage Is Officially Over, FDA Says -- Barrons.com

19. Dez. 2024, 15:02 UTC

Top News

The Zepbound Shortage Is Officially Over, FDA Says -- Barrons.com

16. Dez. 2024, 13:47 UTC

Top News

The Weight-Loss Drug Market Is Heading for a Reckoning This Week -- Barrons.com

16. Dez. 2024, 07:00 UTC

Top News

The Weight-Loss Drug Market Is Heading for a Reckoning This Week. What to Expect. -- Barrons.com

3. Okt. 2024, 14:45 UTC

Top News

Eli Lilly's Weight-Loss Drugs Are No Longer in Short Supply. Bad News for Hims & Hers. -- Barrons.com

Peer-Vergleich

Kursveränderung

Hims & Hers Health Inc Prognose

Kursziel

By TipRanks

1.22% Vorteil

12-Monats-Prognose

Durchschnitt 49 USD  1.22%

Hoch 85 USD

Tief 28 USD

Basierend auf 11 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Hims & Hers Health Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Neutral

11 ratings

2

Buy

7

Halten

2

Sell

Technischer Score

By Trading Central

36.685 / 52.35Unterstützung & Widerstand

Kurzfristig

Bullish Evidence

Mittelfristig

Bullish Evidence

Langfristig

Bullish Evidence

Stimmung

By Acuity

69 / 150 Ranking in Konsumgüter defensiv

Nachrichtenstimmung

Neutral

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Unterdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Hims & Hers Health Inc

Hims & Hers Health, Inc. operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers. It also provides prescription medication on a recurring basis and ongoing care from healthcare providers; and over-the-counter drug and device products, cosmetics, and supplement products primarily focusing on general wellness, sexual health and wellness, skincare, and hair care. In addition, the company's curated non-prescription products include melatonin and biotin in the wellness specialty category; moisturizers, creams, sunscreen, serum, face oil, and face wash in the skincare specialty; condoms, climax delay spray and wipes, vibrators, and lubricants in the sexual health and wellness specialty; and shampoos, conditioners, scalp scrubs, and topical treatments, such as minoxidil in the hair care specialty category. Further, it offers medical consultation and post-consultation support services, as well as health and wellness products through wholesale partners. Hims & Hers Health, Inc. is based in San Francisco, California.
help-icon Live chat